Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
---|
08/28/2002 | EP1181272B1 Process for the preparation of pure citalopram |
08/28/2002 | EP1140898B1 Amide and urea derivatives as 5-ht reuptake inhibitors and as 5-ht1b/1d ligands |
08/28/2002 | EP0973731B1 Hydroxamic acid derivatives |
08/28/2002 | EP0918777B1 SELECTED DERIVATIVES OF K-252a |
08/28/2002 | EP0892804B1 Isoxazolidine derivatives |
08/28/2002 | EP0856001B1 Pyrimidine derivatives as 5ht2c receptor antagonists |
08/28/2002 | EP0822828B1 Isolated 55 to 75 kda protein which binds to prion protein |
08/28/2002 | EP0819002B1 USE OF IMIDAZO-[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA |
08/28/2002 | CN1366526A Process for preparation of pure citalopram |
08/28/2002 | CN1366525A Method for preparation of pure citalopram |
08/28/2002 | CN1366521A Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators |
08/28/2002 | CN1366520A Medicine |
08/28/2002 | CN1366519A Phenoxazine compounds, its pharmaceutical compositions and medical use |
08/28/2002 | CN1365973A New cycloheplene compound, its preparation method and medicine composition containing same |
08/28/2002 | CN1365812A Nano medicine 'Hongling' and its preparing process |
08/28/2002 | CN1365808A Nano medicine 'Guilu Bushen' and its preparing process |
08/28/2002 | CN1365807A Nano medicine 'Kanlisha' and its preparing process |
08/28/2002 | CN1365794A Nano medicine 'Xingnaojing' and its preparing process |
08/28/2002 | CN1365785A Nano medicine 'Anshen Buxin' and its preparing process |
08/28/2002 | CN1365775A Nano medicine 'Niuhuang Zhenjing' and its preparing process |
08/28/2002 | CN1365765A Nano medicine 'Zhuangyuan' and its preparing process |
08/28/2002 | CN1365760A Nano medicine 'Zhuli Datan' and its preparing process |
08/28/2002 | CN1365755A Nano medicine 'Yuzhen' and its preparing process |
08/28/2002 | CN1365754A Nano medicine 'Yixian' and its preparing process |
08/28/2002 | CN1365749A Nano medicine 'Xiongju Shangqing' and its preparing process |
08/28/2002 | CN1365720A Nano 25-component pearl medicine and its preparing process |
08/28/2002 | CN1365700A Nano 25-component coral medicine and its preparing process |
08/28/2002 | CN1365697A Nano medicine 'Naoling' and its preparing process |
08/28/2002 | CN1089765C 1H-pyrido [3,4-b] indole-4-carboxamide derivatives, preparation and application thereof in therapeutics |
08/28/2002 | CN1089764C Substituted heterocyclic compounds, preparation method thereof and pharmaceutical compositions containing same |
08/28/2002 | CN1089762C Benzimidazole compounds and their use as modulators of GABAA receptor complex |
08/28/2002 | CN1089759C Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
08/28/2002 | CN1089585C Use of levobupivacaine in facial surgery |
08/27/2002 | US6441165 Process for the preparation of 11-amino-3-chloro-6, 11-dihydro-5, 5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine and application to the synthesis of tianeptine |
08/27/2002 | US6441153 Human carboxypeptidases and polynucleotides encoding the same |
08/27/2002 | US6441149 Isolated nucleic acids |
08/27/2002 | US6441049 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
08/27/2002 | US6441048 Methods of treating affective disorders using derivatives of (-)-venlafaxine |
08/27/2002 | US6441015 Tetrazole compounds as thyroid receptor ligands |
08/27/2002 | US6441014 Antiinflammatory agent, useful for treating cylcoocygenase-2 associated disorders |
08/27/2002 | US6441013 5-ht6 receptor antagonists for treating central nervous system disorders |
08/27/2002 | US6441012 Chemical compounds |
08/27/2002 | US6441011 Combined preparation consisting of 2-methylthiazolidine-2,4-dicarboxylic acid and paracetamol |
08/27/2002 | US6441007 Treating central nervous system disorders with pyridyloxylalkylamines and phenoxyalkylamines |
08/27/2002 | US6441006 Pharmaceutical compositions and methods for use |
08/27/2002 | US6441000 Compounds useful in therapy |
08/27/2002 | US6440996 Monomeric and dimeric heterocycles, and therapeutic uses thereof |
08/27/2002 | US6440995 Quinolin-4-yl derivatives |
08/27/2002 | US6440991 Ethers of 7-desmethlrapamycin |
08/27/2002 | US6440979 Aryl isoguanines |
08/27/2002 | US6440976 Iminopyrimidine NMDA NR2B receptor antagonists |
08/27/2002 | US6440973 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
08/27/2002 | US6440970 Pharmaceutical compositions and methods for use |
08/27/2002 | US6440969 Certain isoquinolinamine and phthalazinamine derivatives: corticotropin-releasing factor receptor CRF1 specific ligands |
08/27/2002 | US6440968 Use of maduraohtalazine derivatives as inhibitors of proinflammatory cytokines |
08/27/2002 | US6440966 Benzenesulfonamide derivatives and their use as MEK inhibitors |
08/27/2002 | US6440965 Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
08/27/2002 | US6440960 An oxygen or sulfure or sulfure oxide or dioxide containing tricyclic compouund useful for treating the disorder manifesting hypersecretion of corticotropin releasing factor |
08/27/2002 | US6440955 Anti-inflammatory agents |
08/27/2002 | US6440953 Use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. |
08/27/2002 | US6440742 Recombinant AAV vector-based transduction system and use of same |
08/27/2002 | US6440702 For treatment of motor neuron diseases and muscle degenerative diseases; screening for therapeutic proteins by determining altered electrophoretic binding properties |
08/27/2002 | US6440457 Administering venlafaxine antidepressant time-release agent; sustained release |
08/27/2002 | US6440455 Methods for modulating the axonal outgrowth of central nervous system neurons |
08/27/2002 | US6440387 For decreasing blood cholesterol levels, thereby decreasing risk for developing alzheimer's disease; for post menopausal women |
08/27/2002 | CA2167039C Alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them |
08/27/2002 | CA2125888C Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
08/27/2002 | CA2062837C 8-substituted purines as selective adenosine receptor agents |
08/27/2002 | CA2045955C Indole derivatives |
08/22/2002 | WO2002065136A2 Yeast screens for agents affecting protein folding |
08/22/2002 | WO2002064796A2 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
08/22/2002 | WO2002064795A2 Putative human enzymes |
08/22/2002 | WO2002064792A2 Molecules for disease detection and treatment |
08/22/2002 | WO2002064787A1 Neurotonin and use thereof |
08/22/2002 | WO2002064785A1 NOVEL CLOCK GENE Bmal2 |
08/22/2002 | WO2002064781A2 Regulation of amyloid precursor protein expression by modification of abc transporter expression or activity |
08/22/2002 | WO2002064776A2 Signal transduction proteins 15b3, 15b3-1 and 15b3-2, and related dna sequences |
08/22/2002 | WO2002064772A1 Human nmda receptor splice variant |
08/22/2002 | WO2002064755A2 Post-partum mammalian placenta, its use and placental stem cells therefrom |
08/22/2002 | WO2002064748A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
08/22/2002 | WO2002064742A2 Compounds effecting neuron remodeling and assays for same |
08/22/2002 | WO2002064735A2 Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 |
08/22/2002 | WO2002064734A2 Identification of target-specific folding sites in peptides and proteins |
08/22/2002 | WO2002064731A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
08/22/2002 | WO2002064635A1 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
08/22/2002 | WO2002064634A2 Human monoclonal antibodies to fc alpha receptor (cd89) |
08/22/2002 | WO2002064627A2 Crystallization of igf-1 |
08/22/2002 | WO2002064616A2 Agonists and antagonists of sphingosine-1-phosphate receptors |
08/22/2002 | WO2002064612A2 Human g-protein chemokine receptor (ccr5) hdgnr10 |
08/22/2002 | WO2002064603A1 Procedure for the preparation of pure phosphatides and their use in the cosmetic, pharmaceutical and alimentary fields |
08/22/2002 | WO2002064599A1 Bicyclic pyrimidine matrix metalloproteinase inhibitors |
08/22/2002 | WO2002064598A1 Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
08/22/2002 | WO2002064595A1 Triazolo compounds as mmp inhibitors |
08/22/2002 | WO2002064594A2 6-substituted pyrido-pyrimidines |
08/22/2002 | WO2002064592A1 Tricyclic crf receptor antagonists |
08/22/2002 | WO2002064590A2 Carboline derivatives |
08/22/2002 | WO2002064589A1 Laulimalide derivatives |
08/22/2002 | WO2002064586A2 Heterocyclic inhibitors of erk2 and uses thereof |
08/22/2002 | WO2002064584A1 Phthalayinone-piperidino-derivatives as pde4 inhibitors |
08/22/2002 | WO2002064578A1 Benzo thiadiazine matrix metalloproteinase inhibitors |